What do cancer-specific CD8+ T cells see? The contribution of immunopeptidomics
B Nicholas, P Skipp - Essays in Biochemistry, 2023 - portlandpress.com
Immunopeptidomics is the survey of all peptides displayed on a cell or tissue when bound to
human leukocyte antigen (HLA) molecules using tandem mass spectrometry. When …
human leukocyte antigen (HLA) molecules using tandem mass spectrometry. When …
Epigenetic modulation and prostate cancer: Paving the way for NK cell anti-tumor immunity
FD Dos Reis, C Jerónimo, MP Correia - Frontiers in Immunology, 2023 - frontiersin.org
Immunoepigenetics is a growing field, as there is mounting evidence on the key role played
by epigenetic mechanisms in the regulation of tumor immune cell recognition and control of …
by epigenetic mechanisms in the regulation of tumor immune cell recognition and control of …
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia
DC Kirkey, AM Loeb, S Castro, CN McKay… - Blood …, 2023 - ashpublications.org
Abstract Preferentially Expressed Antigen in Melanoma (PRAME), a cancer-testis antigen,
provides an ideal target for immunotherapy in acute myeloid leukemia (AML). We have …
provides an ideal target for immunotherapy in acute myeloid leukemia (AML). We have …
A spatial transcriptome reveals changes in tumor and tumor microenvironment in oral cancer with acquired resistance to immunotherapy
Y Iwasa, T Nakajima, K Hori, Y Yokota, R Kitoh… - Biomolecules, 2023 - mdpi.com
Although anti-programmed death-1 (PD-1) antibody therapy improves the prognosis in
patients with head and neck squamous cell carcinoma (HNSCC), some patients exhibit …
patients with head and neck squamous cell carcinoma (HNSCC), some patients exhibit …
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma
N Dong, L Perez-Lamas, JC Chavez - Expert Opinion on Emerging …, 2023 - Taylor & Francis
Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive
lymphoma. Recent advances in immunotherapy such as chimeric antigen receptor T-cell …
lymphoma. Recent advances in immunotherapy such as chimeric antigen receptor T-cell …
Harnessing the molecular fingerprints of B cell lymphoma for precision therapy
AA Mensah, P Mondello - Journal of clinical medicine, 2022 - mdpi.com
The last two decades have brought ground-breaking advances in genetics, culminating in
deep profiling of the human genome and high resolution detection of genetic variants. These …
deep profiling of the human genome and high resolution detection of genetic variants. These …
[HTML][HTML] MHC 在肿瘤中的研究进展
李君娜, 崔文丽 - Advances in Clinical Medicine, 2024 - hanspub.org
弥漫大B 细胞淋巴瘤(diffuse large B cell lymphoma, DLBCL) 是非霍奇金淋巴瘤(non-Hodgkin
lymphoma, NHL) 中最常见的类型, 个体间有很强的异质性, 1/3 患者在治疗中出现耐药 …
lymphoma, NHL) 中最常见的类型, 个体间有很强的异质性, 1/3 患者在治疗中出现耐药 …
[引用][C] The Scientific Rationale for Targeting Tumor‐Associated Antigens
JS Delisle, MF Aubin - … vol 2‐Immunologic Approaches for the …, 2024 - Wiley Online Library
Multiple types of MHC‐associated antigens can be targeted in lymphoid malignancies.
Tumor‐associated antigens (TAA) are abnormally expressed self‐antigens. TAA‐based …
Tumor‐associated antigens (TAA) are abnormally expressed self‐antigens. TAA‐based …